U.S. Physical Therapy, Inc. (USPH) Key Metrics
USPH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.28B
- Enterprise value
- $1.60B
- P/E (TTM)
- 476.2 10-yr median 50.5
- Forward P/E
- 27.2
- PEG ratio
- 2.73
- Price / sales
- 1.6 10-yr median 2.3
- Price / book
- 2.8 10-yr median 4.3
- EV / EBITDA
- 15.9 10-yr median 17.8
- Dividend yield
- 2.15% $1.84 a year
- Beta
- 1.11
USPH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsUSPH valuation Price multiples at each fiscal year-end price.
USPH returns How much profit the business earns on the capital it uses.
USPH per-share figures Results divided by the shares outstanding at year-end.
USPH financial health Debt, liquidity and how easily interest is covered.
USPH efficiency & capital use Working capital cycle and where the cash goes.
USPH valuation history
USPH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
USPH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
USPH cash returned to shareholders
USPH price vs earnings per share
USPH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.19B | $1.34B | $1.32B | $1.05B | $1.23B | $1.54B | $1.46B | $1.30B | $907.6M | $877.5M |
| Enterprise value | $1.58B | $1.59B | $1.43B | $1.32B | $1.43B | $1.62B | $1.57B | $1.31B | $946.4M | $909.3M |
| P/E ratio | 78.7 | 50.5 | 90.1 | 37.2 | 44.3 | 50.5 | 51.8 | 128.3 | 40.8 | 42.7 |
| Price / sales | 1.5 | 2.0 | 2.2 | 1.9 | 2.5 | 3.6 | 3.0 | 2.9 | 2.2 | 2.5 |
| Price / book | 2.5 | 2.7 | 2.8 | 3.3 | 4.2 | 5.6 | 6.1 | 6.0 | 4.4 | 4.7 |
| Price / free cash flow | 19.4 | 20.3 | 18.2 | 20.9 | 18.1 | 16.7 | 27.9 | 19.7 | 18.4 | 20.5 |
| Price / operating cash flow | 15.8 | 17.8 | 16.1 | 18.0 | 16.1 | 15.4 | 23.4 | 17.8 | 16.1 | 17.2 |
| EV / sales | 2.0 | 2.4 | 2.4 | 2.4 | 2.9 | 3.8 | 3.3 | 2.9 | 2.3 | 2.6 |
| EV / EBITDA | 14.4 | 18.3 | 19.2 | 17.3 | 16.6 | 20.9 | 18.9 | 18.2 | 14.7 | 15.6 |
| EV / free cash flow | 25.8 | 24.2 | 19.6 | 26.2 | 20.9 | 17.6 | 30.1 | 19.9 | 19.1 | 21.2 |
| Earnings yield | 1.3% | 2.0% | 1.1% | 2.7% | 2.3% | 2.0% | 1.9% | 0.8% | 2.5% | 2.3% |
| Free cash flow yield | 5.1% | 4.9% | 5.5% | 4.8% | 5.5% | 6.0% | 3.6% | 5.1% | 5.4% | 4.9% |
| Dividend yield | 2.3% | 2.0% | 1.8% | 2.0% | 1.5% | 0.3% | 1.0% | 0.9% | 1.1% | 1.0% |
| Shareholder yield (dividends + buybacks) | 2.8% | 2.0% | 1.8% | 2.0% | 1.5% | 0.3% | 1.0% | 0.9% | 1.4% | 1.1% |
| Share price at fiscal year-end | $78.09 | $88.71 | $93.14 | $81.03 | $95.55 | $120.25 | $114.35 | $102.35 | $72.20 | $70.20 |
| Per share | ||||||||||
| Revenue per share | $51.47 | $44.57 | $42.63 | $42.60 | $38.38 | $32.95 | $37.78 | $35.84 | $32.94 | $28.52 |
| Earnings per share | $0.99 | $1.76 | $1.03 | $2.18 | $2.16 | $2.38 | $2.21 | $0.80 | $1.77 | $1.64 |
| Operating cash flow per share | $4.95 | $4.97 | $5.78 | $4.51 | $5.92 | $7.79 | $4.90 | $5.76 | $4.50 | $4.08 |
| Free cash flow per share | $4.02 | $4.36 | $5.12 | $3.87 | $5.29 | $7.20 | $4.10 | $5.20 | $3.93 | $3.42 |
| Cash per share | $2.34 | $2.75 | $10.77 | $2.43 | $2.21 | $2.56 | $1.85 | $1.84 | $1.74 | $1.60 |
| Book value per share | $31.40 | $32.46 | $33.56 | $24.32 | $22.92 | $21.52 | $18.83 | $17.05 | $16.30 | $15.00 |
| Tangible book value per share | −$25.62 | −$23.73 | −$10.08 | −$22.11 | −$17.48 | −$9.80 | −$10.19 | −$9.98 | −$9.18 | −$6.19 |
| Dividends per share | $1.80 | $1.76 | $1.70 | $1.64 | $1.45 | $0.32 | $1.14 | $0.92 | $0.80 | $0.68 |
| Capex per share | $0.93 | $0.61 | $0.66 | $0.64 | $0.64 | $0.60 | $0.80 | $0.57 | $0.56 | $0.66 |
| Debt per share | $28.06 | $19.60 | $18.23 | $22.74 | $17.30 | $8.65 | $10.81 | $3.15 | $4.83 | $4.15 |
| Shares outstanding | 15.2M | 15.1M | 14.2M | 13.0M | 12.9M | 12.8M | 12.8M | 12.7M | 12.6M | 12.5M |
| Change in shares outstanding | +0.7% | +6.2% | +9.3% | +0.7% | +0.5% | +0.6% | +0.7% | +0.8% | +0.6% | +0.9% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 3.1% | 5.5% | 3.7% | 9.2% | 9.7% | 11.8% | 12.3% | 4.8% | 11.3% | 11.7% |
| Return on invested capital (ROIC) | 7.5% | 7.2% | 6.8% | 8.3% | 13.2% | 11.8% | 18.6% | 20.6% | 19.4% | 16.4% |
| Return on assets (ROA) | 1.3% | 2.4% | 1.6% | 3.5% | 4.1% | 5.3% | 5.6% | 2.3% | 5.8% | 6.5% |
| Return on tangible assets | 4.4% | 8.2% | 3.9% | 11.1% | 12.2% | 15.9% | 14.8% | 10.0% | 22.6% | 23.8% |
| Free cash flow margin | 7.8% | 9.8% | 12.0% | 9.1% | 13.8% | 21.8% | 10.8% | 14.5% | 11.9% | 12.0% |
| Income quality (OCF / net income) | 4.98 | 2.83 | 5.59 | 2.07 | 2.75 | 3.27 | 2.22 | 7.23 | 2.54 | 2.48 |
| Financial health | ||||||||||
| Total debt | $425.7M | $295.2M | $258.6M | $295.3M | $223.1M | $111.0M | $137.8M | $39.8M | $60.8M | $51.8M |
| Cash & short-term investments | $35.6M | $41.4M | $152.8M | $31.6M | $28.6M | $32.9M | $23.5M | $23.4M | $21.9M | $20.0M |
| Net debt | $390.2M | $253.9M | $105.8M | $263.7M | $194.5M | $78.1M | $114.3M | $16.5M | $38.8M | $31.8M |
| Debt / equity | 0.89 | 0.60 | 0.54 | 0.94 | 0.75 | 0.40 | 0.57 | 0.18 | 0.30 | 0.28 |
| Debt / assets | 0.35 | 0.25 | 0.26 | 0.34 | 0.30 | 0.19 | 0.25 | 0.09 | 0.15 | 0.15 |
| Net debt / EBITDA | 3.56 | 2.92 | 1.42 | 3.47 | 2.27 | 1.01 | 1.38 | 0.23 | 0.60 | 0.54 |
| Current ratio | 1.01 | 1.18 | 2.28 | 1.30 | 1.14 | 0.94 | 1.41 | 1.89 | 1.95 | 2.68 |
| Quick ratio | 1.01 | 1.18 | 2.31 | 1.33 | 1.14 | 0.94 | 1.41 | 1.89 | 1.95 | 2.68 |
| Interest coverage | 8.5 | 7.9 | 5.6 | 9.8 | 75.0 | 32.1 | 32.4 | 29.5 | 2.6 | 4.3 |
| Working capital | $950,000 | $21.3M | $131.2M | $25.8M | $11.7M | −$5.9M | $24.8M | $37.3M | $37.5M | $41.3M |
| Invested capital | $866.6M | $742.8M | $582.0M | $579.5M | $490.1M | $354.2M | $354.5M | $232.4M | $243.7M | $219.3M |
| Tangible asset value | −$95.1M | −$87.4M | $33.0M | −$118.3M | −$68.6M | $8.0M | $9.2M | $8.5M | −$11.3M | −$7.0M |
| Net current asset value | −$293.8M | −$270.8M | −$111.6M | −$262.3M | −$201.8M | −$96.8M | −$96.0M | −$13.1M | −$32.9M | −$27.4M |
| Graham number | $26.48 | $35.82 | $27.95 | $34.51 | $33.35 | $33.95 | $30.58 | $17.49 | $25.48 | $23.56 |
| Graham net-net per share | −$21.88 | −$20.10 | −$9.95 | −$22.44 | −$17.18 | −$8.82 | −$9.08 | −$2.40 | −$4.00 | −$3.38 |
| Capital allocation | ||||||||||
| Dividends paid | $27.4M | $26.5M | $24.1M | $21.3M | $18.8M | $4.1M | $14.6M | $11.7M | $10.1M | $8.5M |
| Share buybacks (net) | $5.6M | $0 | $0 | — | $0 | — | $0 | $265,000 | $2.4M | $1.3M |
| Dividend payout ratio | 181.7% | 100.3% | 164.4% | 75.4% | 67.5% | 13.4% | 51.7% | 115.5% | 45.2% | 41.4% |
| Dividends + buybacks / free cash flow | 54.0% | 40.4% | 33.2% | 42.4% | 27.5% | 4.5% | 27.9% | 18.1% | 25.1% | 22.8% |
| Capex / revenue | 1.8% | 1.4% | 1.5% | 1.5% | 1.7% | 1.8% | 2.1% | 1.6% | 1.7% | 2.3% |
| Capex / operating cash flow | 18.7% | 12.3% | 11.3% | 14.1% | 10.7% | 7.6% | 16.3% | 9.9% | 12.6% | 16.2% |
| Capex / depreciation | 0.63 | 0.49 | 0.59 | 0.56 | 0.71 | 0.73 | 1.01 | 0.74 | 0.73 | 0.94 |
| Stock-based compensation / revenue | 1.1% | 1.2% | 1.2% | 1.3% | 1.6% | 1.9% | 1.4% | 1.3% | 1.2% | 1.4% |
| SG&A / revenue | — | 8.7% | 10.2% | 8.3% | 9.4% | 9.9% | 9.3% | 9.1% | 8.7% | 9.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 40.7 | 42.2 | 42.0 | 43.5 | 41.8 | 46.2 | 40.7 | 41.0 | 40.5 | 41.0 |
| Days of inventory on hand | — | — | -2.1 | -1.2 | 0.0 | 0.0 | 0.0 | — | — | 0.0 |
| Days payables outstanding | 3.5 | 3.3 | 3.9 | 5.4 | 3.8 | 2.1 | 2.2 | 2.2 | 2.1 | 2.2 |
| Cash conversion cycle (days) | 37.2 | 39.0 | 35.9 | 36.9 | 38.0 | 44.0 | 38.5 | 38.8 | 38.3 | 38.8 |
| Receivables turnover | 8.98 | 8.64 | 8.70 | 8.40 | 8.73 | 7.91 | 8.96 | 8.91 | 9.02 | 8.90 |
| Payables turnover | 103.98 | 111.33 | 92.92 | 68.00 | 96.81 | 171.60 | 163.75 | 168.38 | 170.27 | 167.91 |
| Inventory turnover | — | — | — | — | 377,840,000.00 | 328,519,000.00 | 369,495,000.00 | — | — | 549,068,000.00 |
| Asset turnover | 0.66 | 0.62 | 0.65 | 0.69 | 0.74 | 0.73 | 0.96 | 1.05 | 1.08 | 1.13 |
| Average receivables | $87.0M | $77.7M | $69.5M | $65.9M | $56.7M | $53.5M | $53.8M | $50.9M | $45.9M | $40.1M |
| Average payables | $6.0M | $4.9M | $5.2M | $6.5M | $3.9M | $1.9M | $2.3M | $2.1M | $1.9M | $1.6M |
| Average inventory | — | — | −$2.8M | −$1.4M | $1 | $1 | $1 | — | $0 | $0 |
| Intangibles / total assets | 71.9% | 72.5% | 62.1% | 70.3% | 69.5% | 67.6% | 66.0% | 77.3% | 76.4% | 75.4% |
Computed from USPH's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
USPH valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), U.S. Physical Therapy traded at 78.7 times earnings, against a 10-year median of 50.5. Based on the latest twelve months, the trailing P/E is 476.2 and the forward P/E is 27.2. U.S. Physical Therapy earned a return on equity of 3.1% and a return on invested capital of 7.5% in fiscal 2025. It ended the year with $425.7 million of debt and $35.6 million in cash and short-term investments, net debt of $390.2 million. It returned $32.9 million to shareholders: $27.4 million in dividends and $5.6 million in share buybacks, 54% of free cash flow. The share count rose 21.4% from 12.5M to 15.2M over 9 years.
See the USPH income statement, the USPH chart for price history, or the USPH stock overview for the latest quote and news.
USPH key metrics FAQ
What is U.S. Physical Therapy's P/E ratio?
U.S. Physical Therapy's trailing P/E ratio is 476.2 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 27.2. At the end of fiscal 2025 it was 78.7, compared with a 10-year median of 50.5.
What is U.S. Physical Therapy's EV/EBITDA?
U.S. Physical Therapy's enterprise value was 14.4 times EBITDA at the end of fiscal 2025 (enterprise value $1.6 billion, EBITDA $109.7 million); the current EV/EBITDA is 15.9.
What is U.S. Physical Therapy's return on equity?
U.S. Physical Therapy's return on equity (ROE) was 3.1% in fiscal 2025: net income of $15.1 million on average shareholders' equity of $482.7 million.
What is U.S. Physical Therapy's ROIC?
U.S. Physical Therapy's return on invested capital was 7.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does U.S. Physical Therapy have?
U.S. Physical Therapy had total debt of $425.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.89 and $390.2 million of net debt (3.56 times EBITDA).
What is U.S. Physical Therapy's dividend yield?
U.S. Physical Therapy's forward dividend yield is 2.15%. U.S. Physical Therapy paid $27.4 million in dividends in fiscal 2025 ($1.80 per share), a payout ratio of 181.7%.
Does U.S. Physical Therapy buy back its shares?
Yes. U.S. Physical Therapy spent $5.6 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.7% over the year, to 15.2M..
What is U.S. Physical Therapy's free cash flow yield?
U.S. Physical Therapy generated $61.0 million of free cash flow in fiscal 2025, a free cash flow yield of 5.1% on its market value at year-end ($1.2 billion).
What is U.S. Physical Therapy's current ratio?
U.S. Physical Therapy's current ratio was 1.01 at the end of fiscal 2025: current assets were 1.01 times current liabilities.